230 related articles for article (PubMed ID: 19370533)
1. [Toxicity and efficacy of intermittent docetaxel chemotherapy for hormone refractory prostate cancer].
Olbert PJ; Weil C; Hegele A; Hofmann R; Schrader AJ
Aktuelle Urol; 2009 May; 40(3):164-8. PubMed ID: 19370533
[TBL] [Abstract][Full Text] [Related]
2. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study.
Tiffany NM; Ryan CW; Garzotto M; Wersinger EM; Beer TM
J Urol; 2005 Sep; 174(3):888-92. PubMed ID: 16093981
[TBL] [Abstract][Full Text] [Related]
3. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience.
Boehmer A; Anastasiadis AG; Feyerabend S; Nagele U; Kuczyk M; Schilling D; Corvin S; Merseburger AS; Stenzl A
Anticancer Res; 2005; 25(6C):4481-6. PubMed ID: 16334130
[TBL] [Abstract][Full Text] [Related]
5. Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study.
Font A; Murias A; Arroyo FR; Martin C; Areal J; Sanchez JJ; Santiago JA; Constenla M; Saladie JM; Rosell R
Ann Oncol; 2005 Mar; 16(3):419-24. PubMed ID: 15668260
[TBL] [Abstract][Full Text] [Related]
6. [Significance of docetaxel in the chemotherapy of hormone-refractory prostate cancer].
Wolff JM
Onkologie; 2003 Dec; 26 Suppl 7():37-40. PubMed ID: 14716141
[TBL] [Abstract][Full Text] [Related]
7. [Low-dose docetaxel, estramustine and dexamethasone combination chemotherapy for hormone-refractory prostate cancer].
Kobayashi K; Yokonishi T; Ito Y; Matsumoto T; Umemoto S; Osaka K; Nakamura M; Onuki T; Komiya A; Ohgo Y; Sakai N; Noguchi S; Kishi H; Yokomizo Y; Kawai M; Okajima K; Tajiri T; Fujikawa A; Ohta J; Yumura Y; Moriyama M
Hinyokika Kiyo; 2010 Apr; 56(4):203-7. PubMed ID: 20448443
[TBL] [Abstract][Full Text] [Related]
8. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?
Michels J; Montemurro T; Murray N; Kollmannsberger C; Nguyen Chi K
Cancer; 2006 Mar; 106(5):1041-6. PubMed ID: 16456811
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
Oh WK; Hagmann E; Manola J; George DJ; Gilligan TD; Jacobson JO; Smith MR; Kaufman DS; Kantoff PW
Clin Cancer Res; 2005 Jan; 11(1):284-9. PubMed ID: 15671557
[TBL] [Abstract][Full Text] [Related]
10. Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).
Kattan JG; Farhat FS; Chahine GY; Nasr FL; Moukadem WT; Younes FC; Yazbeck NJ; Ghosn MG;
Invest New Drugs; 2008 Feb; 26(1):75-9. PubMed ID: 17846704
[TBL] [Abstract][Full Text] [Related]
11. Future directions in the treatment of androgen-independent prostate cancer.
Petrylak DP
Urology; 2005 Jun; 65(6 Suppl):8-12. PubMed ID: 15939077
[TBL] [Abstract][Full Text] [Related]
12. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
[TBL] [Abstract][Full Text] [Related]
13. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis.
Hahn NM; Marsh S; Fisher W; Langdon R; Zon R; Browning M; Johnson CS; Scott-Horton TJ; Li L; McLeod HL; Sweeney CJ
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6094-9. PubMed ID: 17062685
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Petrylak DP; Tangen CM; Hussain MH; Lara PN; Jones JA; Taplin ME; Burch PA; Berry D; Moinpour C; Kohli M; Benson MC; Small EJ; Raghavan D; Crawford ED
N Engl J Med; 2004 Oct; 351(15):1513-20. PubMed ID: 15470214
[TBL] [Abstract][Full Text] [Related]
15. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
[TBL] [Abstract][Full Text] [Related]
16. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
Van Poppel H
Can J Urol; 2005 Feb; 12 Suppl 1():81-5. PubMed ID: 15780173
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of sequential chemotherapy with docetaxel-estramustine followed by mitoxantrone-prednisone in patients with advanced hormone-refractory prostate cancer.
Galli L; Fontana A; Galli C; Landi L; Fontana E; Antonuzzo A; Andreuccetti M; Aitini E; Barbieri R; Di Marsico R; Falcone A
Br J Cancer; 2007 Dec; 97(12):1613-7. PubMed ID: 18026196
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer.
Eymard JC; Priou F; Zannetti A; Ravaud A; Lepillé D; Kerbrat P; Gomez P; Paule B; Genet D; Hérait P; Ecstein-Fraïssé E; Joly F
Ann Oncol; 2007 Jun; 18(6):1064-70. PubMed ID: 17434899
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.
Kreis W; Budman DR; Fetten J; Gonzales AL; Barile B; Vinciguerra V
Ann Oncol; 1999 Jan; 10(1):33-8. PubMed ID: 10076719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]